Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Mainz Biomed (MYNZ) Equity Average (2021 - 2025)

Mainz Biomed's Equity Average history spans 4 years, with the latest figure at $4.6 million for Q4 2024.

  • For Q4 2024, Equity Average fell 46.41% year-over-year to $4.6 million; the TTM value through Dec 2024 reached $4.6 million, down 46.41%, while the annual FY2024 figure was $4.6 million, 46.41% down from the prior year.
  • Equity Average for Q4 2024 was $4.6 million at Mainz Biomed, down from $8.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $10.2 million in Q4 2022 and bottomed at $1.8 million in Q4 2021.
  • The 4-year median for Equity Average is $6.7 million (2023), against an average of $6.3 million.
  • The largest annual shift saw Equity Average soared 465.18% in 2022 before it crashed 46.41% in 2024.
  • A 4-year view of Equity Average shows it stood at $1.8 million in 2021, then skyrocketed by 465.18% to $10.2 million in 2022, then dropped by 15.21% to $8.7 million in 2023, then tumbled by 46.41% to $4.6 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Equity Average are $4.6 million (Q4 2024), $8.7 million (Q4 2023), and $10.2 million (Q4 2022).